Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration

Retina

Volumn 30, Issue 7, 2010, Pages 1025-1033

  Pedersen, Karen Bjerg ^a   Møller, Flemming ^a   Sjølie, Anne Katrin ^a   Andréasson, Sten ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTRORETINOGRAPHY; FEMALE; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PILOT STUDY; PROSPECTIVE STUDY; RETINA; RETINA CONE; RETINA MACULA AGE RELATED DEGENERATION; RETINA ROD; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; ELECTROPHYSIOLOGY; ELECTRORETINOGRAPHY; FEMALE; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 77954712963     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181cafc8f     Document Type: Article

References (32)

1. Hee MR, Izatt JA, Swanson EA, et al. Optical coherence tomography of the human retina. Arch Ophthalmol 1995;113: 325-332.
2. Walter P, Widder RA, Luke C, Konigsfeld P, Brunner R. Electrophysiological abnormalities in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 1999;237: 962-968.
3. Sunness JS, Massof RW, Johnson MA, Finkelstein D, Fine SL. Peripheral retinal function in age-related macular degeneration. Arch Ophthalmol 1985;103:811-816.
4. Holopigian K, Seiple W, Greenstein V, Kim D, Carr RE. Relative effects of aging and age-related macular degeneration on peripheral visual function. Optom Vis Sci 1997;74: 152-159.
5. Sutter EE, Tran D. The field topography of ERG components in man-I. The photopic luminance response. Vision Res 1992; 32:433-446.
6. Hood DC, Frishman LJ, Saszik S, Viswanathan S. Retinal origins of the primate multifocal ERG: implications for the human response. Invest Ophthalmol Vis Sci 2002;43: 1673-1685.
7. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-335.
8. Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 2007;12:713-718.
9. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262-269.
10. Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravitreal toxicity of bevacizumab (Avastin). Retina 2006;26: 257-261.
11. Luke M, Warga M, Ziemssen F, et al. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006;90:1178-1182.
12. Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG. Preclinical safety evaluation of intravitreal injection of fulllength humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 2007;48:1773-1781.
13. Maturi RK, Bleau LA,Wilson DL. Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 2006;26:270-274.
14. Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C, Loukianou E, Moschos M. Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal- ERG after use of bevacizumab in ARMD. Doc Ophthalmol 2007;114:37-44.
15. Karanjia R, Eng KT, Gale J, Sharma S, ten Hove MW. Electrophysiological effects of intravitreal Avastin (bevacizumab) in the treatment of exudative age-related macular degeneration. Br J Ophthalmol 2008;92:1248-1252.
16. Liu Y, Wen F, Li J, Zuo C, Li M. Transitions of multifocal electroretinography in patients with age-related macular degeneration after combination therapy with photodynamic therapy and intravitreal bevacizumab. Doc Ophthalmol 2009 Aug 15 [Epub ahead of print].
17. Pedersen KB, Sjolie AK, Moller F. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration in treatment-naive patients. Acta Ophthalmol 2008 Dec 16 [Epub ahead of print].
18. Hood DC, Bach M, Brigell M, et al. ISCEV guidelines for clinical multifocal electroretinography (2007 edition). Doc Ophthalmol 2008;116:1-11.
19. Marmor MF, Holder GE, Seeliger MW, Yamamoto S; International Society for Clinical Electrophysiology of Vision. Standard for clinical electroretinography (2004 update). Doc Ophthalmol 2004;108:107-114.
20. Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005;167:1451-1459.
21. Zhao S, Overbeek PA. Regulation of choroid development by the retinal pigment epithelium. Mol Vis 2001;7:277-282.
22. McLeod DS, Taomoto M, Otsuji T, Green WR, Sunness JS, Lutty GA. Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 2002;43:1986-1993.
23. Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz- Schmidt KU; Tübingen Bevacizumab Study Group, Schraermeyer U. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007; 143:995-1002.
24. Ziemssen F, Luke M, Messias A, et al; Tuebingen Bevacizumab Study Group. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 2008;28: 101-109.
25. Shetty R, Pai SA, Vincent A, et al. Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 2008;116:129-135.
26. Stahl A, Feltgen N, Fuchs A, Bach M. Electrophysiological evaluation of retinal photoreceptor function after repeated bevacizumab injections. Doc Ophthalmol 2009;118:81-88.
27. Heiduschka P, Fietz H, Hofmeister S, et al; Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-2823.
28. Sakurai K, Akiyama H, Shimoda Y, Yoshida I, Kurabayashi M, Kishi S. Effect of intravitreal injection of high-dose bevacizumab in monkey eyes. Invest Ophthalmol Vis Sci 2009;50: 4905-4916.
29. Grover S, Fishman GA, Birch DG, Locke KG, Rosner B. Variability of full-field electroretinogram responses in subjects without diffuse photoreceptor cell disease. Ophthalmology 2003;110:1159-1163.
30. Zuo C, Wen F, Li J, Liu Y, Li M. Transitions of multifocal electroretinography following combined intravitreal bevacizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Doc Ophthalmol 2009;119:29-36.
31. Curcio CA, Medeiros NE, Millican CL. Photoreceptor loss in age-related macular degeneration. Invest Ophthalmol Vis Sci 1996;37:1236-1249.
32. Chu PH, Chan HH, Leat SJ. Effects of unsteady fixation on multifocal electroretinogram (mfERG). Graefes Arch Clin Exp Ophthalmol 2006;244:1273-1282.